Journal article
A STATement on vemurafenib-resistant melanoma
Journal of investigative dermatology, v 133(8), pp 1928-1929
01 Aug 2013
PMID: 23856932
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Despite recent advancements in the treatment of late-stage mutant BRAF (V600E/K) melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors such as vemurafenib. The mechanisms for resistance have proven to be heterogeneous, emphasizing the need to use broad therapeutic approaches. In this issue, the study "Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas" by Liu et al. proposes that signal transducer and activator of transcription 3 (STAT3)-paired box 3 (PAX3) signaling may be a mechanism that is used by melanomas to resist RAF inhibitors.
Metrics
Details
- Title
- A STATement on vemurafenib-resistant melanoma
- Creators
- Edward J Hartsough - Sidney Kimmel Cancer CenterAndrew E Aplin - Thomas Jefferson University
- Publication Details
- Journal of investigative dermatology, v 133(8), pp 1928-1929
- Publisher
- Springer Nature
- Grant note
- R01 CA160495 / NCI NIH HHS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:000321939300005
- Scopus ID
- 2-s2.0-84880372025
- Other Identifier
- 991020532107204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Dermatology